A Phase 1, Open-Label, Randomized, Adaptive, Cross-Over Study Evaluating the Bioavailability of Two Formulations of Linifanib and Food Effect on Pharmacokinetics of Linifanib in Subjects with Advanced or Metastatic Solid Tumors (Abbott Laboratories #M12-468).

Trial Profile

A Phase 1, Open-Label, Randomized, Adaptive, Cross-Over Study Evaluating the Bioavailability of Two Formulations of Linifanib and Food Effect on Pharmacokinetics of Linifanib in Subjects with Advanced or Metastatic Solid Tumors (Abbott Laboratories #M12-468).

Discontinued
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2012

At a glance

  • Drugs Linifanib (Primary)
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Most Recent Events

    • 29 Feb 2012 Actual number of patient (14) added as reported by ClinicalTrials.gov.
    • 29 Feb 2012 Actual end date (1 Jan 2012) added as reported by ClinicalTrials.gov.
    • 29 Feb 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top